Home/Pipeline/LY3885125 (AK-OTOF)

LY3885125 (AK-OTOF)

Sensorineural Hearing Loss

Phase 1/2Active

Key Facts

Indication

Sensorineural Hearing Loss

Phase

Phase 1/2

Status

Active

Company

Eli Lilly

About Eli Lilly

Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.

View full company profile

Therapeutic Areas

Diabetes Obesity Oncology Immunology Neuroscience Dermatology Autoimmune Sleep Disorders Migraine

Other Sensorineural Hearing Loss Drugs

Drug	Company	Phase	Status
Lead Cell Therapy Program	Rinri Therapeutics	Phase 1	Active
Rinri Therapeutics Collaboration	Mytos	Pre-clinical/Clinical	Active
ANP1	Lineage Cell Therapeutics	Preclinical	Active